Prostatype Genomics AB
27 Jan - 17 Feb 2022Warrant exercise
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By giving a comprehensive assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Their vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.
Prostatype Genomics’ mission is to make a difference in prostate cancer patients’ lives through the discovery and commercialization of transformative tests to guide treatment decisions. They can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. Prostatype Genomics will achieve this by making Prostatype the global test system of choice for newly diagnosed prostate cancer patients.
Read more on the company's website
The offer in summary
Subscription period: 27 January- 17 February 2022
Price per share: SEK 10.90
Trading with warrant: Until 15 February 2022
Payment day: 17 February 2022
Marketplace: First North Stockholm
Financial advisor: Sedermera Corporate Finance